balticbusinessnews.com ·
atisama therapeutics advances rb042 into multiple ascending dose cohorts of phase 1 trial and appoints bernard coulie as chair of the board
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAtisama Therapeutics, a Melbourne-based biotech, progresses RB042 (a splice-switching oligonucleotide) into Phase 1 multiple ascending dose cohorts for COPD, a disease affecting ~400 million people. The appointment of Bernard Coulie (ex-J&J) adds pulmonary expertise. Commercial mechanism is weak: early-stage clinical data only; no revenue, cost, or supply chain impact yet. Sector PHARMA_BIOTECH is relevant due to drug development pipeline, but magnitude and confidence are low.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- RB042 advanced to multiple ascending dose cohorts in Phase 1 trial.
- Three of four single ascending dose cohorts completed; first multiple ascending dose cohort initiated.
- Higher-dose results expected in second half of 2026.
- Dr. Bernard Coulie appointed Chair of the Board.
- Atisama focuses on splice-switching oligonucleotide therapies for COPD and chronic inflammatory diseases.